Bioconnect CE marks Optiflow anastomotic system
This article was originally published in Clinica
Bioconnect Systems has CE marked its Optiflow vascular anastomotic system for sale in Europe. The device is intended to create arteriovenous fistulae for vascular access in patients on haemodialysis, such as those with end-stage renal disease. Optiflow improves surgeons' ability to create precise vascular connections, Ambler, Pennsylvania-based Bioconnect claims. The firm believes there is an unmet need for therapies that improve fistula function, as around 60% of access sites fail within the four to five months, according to a study by the US National Institutes of Health.